Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives $11.00 Average PT from Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $11.00.

EVAX has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Evaxion A/S in a research report on Friday. Maxim Group initiated coverage on Evaxion A/S in a research report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price target on the stock. Wall Street Zen cut Evaxion A/S from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. JonesTrading initiated coverage on Evaxion A/S in a research report on Tuesday, March 10th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Lake Street Capital lowered their price objective on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, March 9th.

Evaxion A/S Stock Performance

Shares of EVAX opened at $4.18 on Friday. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41. The business’s 50 day moving average price is $3.76 and its 200-day moving average price is $4.71. Evaxion A/S has a 52 week low of $1.42 and a 52 week high of $12.15. The stock has a market cap of $34.86 million, a P/E ratio of -3.17 and a beta of 0.19.

Hedge Funds Weigh In On Evaxion A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EVAX. Northwestern Mutual Wealth Management Co. bought a new position in Evaxion A/S in the 4th quarter valued at approximately $38,000. Wesbanco Bank Inc. bought a new position in Evaxion A/S in the 4th quarter valued at approximately $48,000. Finally, SmartHarvest Portfolios LLC bought a new position in Evaxion A/S in the 4th quarter valued at approximately $72,000. 11.04% of the stock is owned by institutional investors.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.